Cheetah Medical Announces Successful Completion of Key Sepsis Clinical Trial
NEWTON, Mass., March 14, 2019 (BUSINESS WIRE) – Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management, today announced it has concluded enrollment for the Fluid Responsiveness Evaluation in Sepsis-associated Hypotension (FRESH) trial following successful primary outcomes.
The FRESH study, led by Ivor Douglas, M.D., FRCP, Denver Health Medical Center, has enrolled approximately 120 patients over the past two years and is the first multi-center, prospective, randomized, controlled study to evaluate using fluid responsiveness to drive fluid therapy in critically ill septic patients with refractory hypotension in an ICU setting.
“We are very confident in these results and look forward to the final analysis,” said Dr. Douglas. “As this is the first study of its kind, we expect its findings to have a significant impact on the fluid management of patients.”
“Every day, clinicians must decide whether to give fluids or vasopressors to treat hypotensive patients,” said Douglas M. Hansell, M.D., M.P.H., Chief Physician Executive at Cheetah Medical. “The FRESH study was designed to determine whether using stroke-volume guided dynamic measures of fluid effectiveness can help clinicians improve outcomes in these difficult patients.”
The full results of the FRESH study will be submitted for publication in a medical journal anticipated for late 2019.
About the FRESH Study
The Fluid Responsiveness Evaluation in Sepsis-associated Hypotension study (FRESH) is a prospective, randomized, controlled study evaluating the incidence of fluid responsiveness (FR) in critically ill patients with sepsis or septic shock. Upon completion, the FRESH study will assess the mean difference in fluid balance at intensive care unit (ICU) discharge and associated patient outcomes, based on a dynamic assessment of FR in septic patients with refractory hypotension in an ICU setting.
About Cheetah Medical
Cheetah Medical is the pioneer and leading global provider of 100 percent non-invasive fluid management monitoring technologies, designed for use in critical care, operating room and emergency department settings. The CHEETAH Starling™ SV is fast becoming the gold standard in fluid management, as it provides immediate, dynamic assessments of fluid responsiveness, enabling clinicians to make more confident and informed treatment for their patients. Moreover, recent research from the University of Kansas Medical Center has shown effective fluid management can reduce hospital ICU stays by an average of 2.89 days, reduce risk of mechanical ventilation and initiation of acute dialysis, saving over $14,000 in medical costs per patient. The company’s fluid management systems currently make an impact in more than 400 hospitals throughout the U.S. and in 30 countries worldwide.
Could HighCape be the right partner for your growing business?
Contact us for more information.
452 5th Ave, 21st Floor
New York, NY 10018